Dual Antiplatelet therapy much efficient in treating Cardiovascular death: MASTER DAPT Trial

Written By :  MD Editorial Team
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-02-10 03:30 GMT   |   Update On 2022-02-10 03:30 GMT
Advertisement

Cardiac death is greater burden on global health. Fatal heart diseases involve formation of clots in major blood vessels, antiplatelet medicines can stop blood clots from forming. Anticoagulant therapy has established its place in reducing systemic thrombotic events in patients with atrial fibrillation. Efficacy of anticoagulant therapy has established its place in reducing systemic thrombotic events in patients with atrial fibrillation.

Advertisement

The MASTER DAPT trial unravels that abbreviated antiplatelet therapy was non-inferior to standard antiplatelet therapy with regard to net adverse clinical events. The trial evaluated abbreviated antiplatelet therapy compared with standard antiplatelet therapy among patients who underwent percutaneous coronary intervention (PCI) with a biodegradable-polymer sirolimus-eluting stent.

The Findings are published in American College of Cardiology.

Among patients with acute or chronic coronary artery disease who underwent percutaneous coronary intervention within the last 30-44 days and were at increased bleeding risk, abbreviated DAPT was non-inferior to standard DAPT regarding net adverse clinical events and major adverse cardiac or cerebral events.

The results of the trial were

• Net adverse clinical events (all-cause mortality, MI, stroke, or major bleeding) was 7.5% in the abbreviated therapy group compared with 7.7% in the standard therapy group (p < 0.001 for non inferiority)

• Major adverse cardiac or cerebral events (all-cause mortality, MI, or stroke) was 6.1% in the abbreviated therapy group compared with 5.9% in the standard therapy group (p = 0.001 for non inferiority)

• Major or clinically relevant non major bleeding was 6.5% in the abbreviated therapy group compared with 9.4% in the standard therapy group (p < 0.001 for superiority)

Trial concluded that abbreviated DAPT was superior to standard antiplatelet therapy regarding major or clinically relevant non-major bleeding. These results are specific to patients who received a biodegradable-polymer sirolimus-eluting stent. The results were the same among those with and without an indication for oral anticoagulation therapy.

Reference: https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2021/08/25/23/38/MASTER-DAPT

Tags:    
Article Source : American College of Cardiology

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News